Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Completed · Phase 4 · NCT02586623
Conditions: Symptomatic Neurogenic Orthostatic Hypotension
At a glance
- Research payments reported, 2025
- $2,505
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 453
About the trial
- Sponsor
- H. Lundbeck A/S
- Tested
- Droxidopa capsules (drug), Placebo capsules (drug)
- Dates
- Started 2016-02-11; completion 2022-09-09
- Results posted
- Yes
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH) (dizziness, light-headedness, or feelings that they are about to black out)
From ClinicalTrials.gov, last updated 2023-08-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
H. Lundbeck A S reported $2,505 in research payments for this study in 2025 (2 payments).
Products named: Northera
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Detroit Clinical Research Center PC $2,505
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.